688317 之江生物
已收盘 03-24 15:00:01
资讯
新帖
简况
每周股票复盘：之江生物（688317）两产品获马来西亚认证
证券之星 · 03-22 03:00
每周股票复盘：之江生物（688317）两产品获马来西亚认证
之江生物（688317）披露公司产品获得马来西亚医疗器械管理局认证，3月19日股价下跌2.06%
证券之星 · 03-19
之江生物（688317）披露公司产品获得马来西亚医疗器械管理局认证，3月19日股价下跌2.06%
之江生物(688317.SH)：2项产品获得相关认证
智通财经 · 03-19
之江生物(688317.SH)：2项产品获得相关认证
之江生物：累计回购公司股份2065434股
证券日报 · 03-03
之江生物：累计回购公司股份2065434股
之江生物去年营收1.25亿元，已连续三年营收下滑、净利亏损
新京报 · 03-02
之江生物去年营收1.25亿元，已连续三年营收下滑、净利亏损
每周股票复盘：之江生物（688317）2025年净亏3430万
证券之星 · 03-01
每周股票复盘：之江生物（688317）2025年净亏3430万
之江生物发布2025年度业绩快报，亏损0.343亿元
证券之星 · 02-27
之江生物发布2025年度业绩快报，亏损0.343亿元
增持加码三优生物，之江生物深化“诊断+治疗”布局，业绩亏损泥潭待解
证券之星 · 02-27
增持加码三优生物，之江生物深化“诊断+治疗”布局，业绩亏损泥潭待解
之江生物（688317）披露2026年度日常关联交易预计公告，2月25日股价上涨0.43%
证券之星 · 02-25
之江生物（688317）披露2026年度日常关联交易预计公告，2月25日股价上涨0.43%
每周股票复盘：之江生物（688317）回购股份达总股本1.01%
证券之星 · 02-08
每周股票复盘：之江生物（688317）回购股份达总股本1.01%
之江生物（688317）披露2025年第三次以集中竞价交易方式回购公司股份比例达到总股本1%暨回购进展公告，2月2日股价下跌5.05%
证券之星 · 02-02
之江生物（688317）披露2025年第三次以集中竞价交易方式回购公司股份比例达到总股本1%暨回购进展公告，2月2日股价下跌5.05%
每周股票复盘：之江生物（688317）因股价涨幅达15%登龙虎榜
证券之星 · 02-01
每周股票复盘：之江生物（688317）因股价涨幅达15%登龙虎榜
1月26日之江生物（688317）龙虎榜数据：机构净买入1794.7万元
证券之星 · 01-26
1月26日之江生物（688317）龙虎榜数据：机构净买入1794.7万元
异动快报：之江生物（688317）1月26日9点44分触及涨停板
证券之星 · 01-26
异动快报：之江生物（688317）1月26日9点44分触及涨停板
每周股票复盘：之江生物（688317）2025年净利预亏3200万至4700万元
证券之星 · 01-25
每周股票复盘：之江生物（688317）2025年净利预亏3200万至4700万元
之江生物（688317）披露2025年年度业绩预告，1月22日股价下跌0.05%
证券之星 · 01-22
之江生物（688317）披露2025年年度业绩预告，1月22日股价下跌0.05%
之江生物(688317.SH)发预亏，预计2025年度归母净亏损3200万元-4700万元
智通财经 · 01-22
之江生物(688317.SH)发预亏，预计2025年度归母净亏损3200万元-4700万元
之江生物（688317）披露公司产品获得相关认证，01月20日股价下跌0.24%
证券之星 · 01-20
之江生物（688317）披露公司产品获得相关认证，01月20日股价下跌0.24%
之江生物最新公告：公司产品获得马来西亚医疗器械认证
证券之星 · 01-20
之江生物最新公告：公司产品获得马来西亚医疗器械认证
每周股票复盘：之江生物（688317）回购股份181.29万股
证券之星 · 01-11
每周股票复盘：之江生物（688317）回购股份181.29万股
加载更多
公司概况
公司名称：
上海之江生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2021-01-18
主营业务：
上海之江生物科技股份有限公司的主营业务是分子诊断试剂和仪器设备的研发、生产和销售。公司的主要产品是分子诊断试剂和仪器设备。公司共有500多项产品，已形成20大系列，是国内感染性疾病分子诊断产品最为齐全的企业之一，覆盖了绝大多数国家法定传染病。
发行价格：
43.22
{"stockData":{"symbol":"688317","market":"SH","secType":"STK","nameCN":"之江生物","latestPrice":18.91,"timestamp":1774335601000,"preClose":18.45,"halted":0,"volume":1415425,"delay":0,"changeRate":0.0249,"floatShares":192000000,"shares":192000000,"eps":-0.7486,"marketStatus":"已收盘","change":0.46,"latestTime":"03-24 15:00:01","open":18.67,"high":18.95,"low":18.38,"amount":26369700,"amplitude":0.0309,"askPrice":18.91,"askSize":13,"bidPrice":18.9,"bidSize":4,"shortable":0,"etf":0,"ttmEps":-0.7486,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774402200000},"marketStatusCode":5,"adr":0,"adjPreClose":18.45,"symbolType":"stock_kcb","openAndCloseTimeList":[[1774315800000,1774323000000],[1774328400000,1774335600000]],"highLimit":20.3,"lowLimit":16.61,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":192157999,"isCdr":false,"pbRate":1.07,"roa":"--","roe":"--","epsLYR":-0.67,"committee":-0.127413,"marketValue":3634000000,"turnoverRate":0.0074,"status":0,"afterMarket":{"amount":0,"volume":0,"close":18.91,"buyVolume":0,"sellVolume":0,"time":1774337637558,"indexStatus":"已收盘 03-24 15:30:00","preClose":18.45},"floatMarketCap":3634000000},"requestUrl":"/m/hq/s/688317","defaultTab":"news","newsList":[{"id":"2621799169","title":"每周股票复盘：之江生物（688317）两产品获马来西亚认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2621799169","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621799169?lang=zh_cn&edition=full","pubTime":"2026-03-22 03:00","pubTimestamp":1774119638,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，之江生物报收于19.08元，较上周的19.88元下跌4.02%。本周，之江生物3月17日盘中最高价报20.11元。本周关注点公司公告汇总：之江生物两项RNA提取试剂获马来西亚医疗器械认证，有效期均至2031年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2620243092","title":"之江生物（688317）披露公司产品获得马来西亚医疗器械管理局认证，3月19日股价下跌2.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620243092","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620243092?lang=zh_cn&edition=full","pubTime":"2026-03-19 17:10","pubTimestamp":1773911417,"startTime":"0","endTime":"0","summary":"截至2026年3月19日收盘，之江生物报收于19.47元，较前一交易日下跌2.06%，最新总市值为37.41亿元。近日，上海之江生物科技股份有限公司发布《关于自愿披露公司产品获得相关认证的公告》。公告显示，公司两项产品“Viral RNA Isolation Kit ”和“Viral RNA Extraction Kit”近期获得马来西亚医疗器械管理局认证，认证有效期分别为2026年3月6日至2031年3月5日、2026年2月27日至2031年2月26日，适用范围为临床样本中核酸的提取，可在马来西亚及认可该认证的国家销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900027622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09996","BK1100","BK0239","BK1222","688317","BK1583","09997","159883","BK1574"],"gpt_icon":0},{"id":"2620178352","title":"之江生物(688317.SH)：2项产品获得相关认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2620178352","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620178352?lang=zh_cn&edition=full","pubTime":"2026-03-19 15:42","pubTimestamp":1773906164,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 之江生物(688317.SH)发布公告，公司2项产品于近期获得相关认证，分别为：“Viral RNA Isolation Kit (Preloaded for Auto-Extraction) 核酸提取试剂(预装用于自动化提取)”、“ViralRNAExtraction Kit 核酸提取试剂”。上述产品获得认证后，可在马来西亚和认可马来西亚认证的国家进行销售，进一步提升了公司的国际化竞争力，对于公司扩充海外销售产品品类及国际业务拓展具有积极作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"之江生物(688317.SH)：2项产品获得相关认证","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2616239303","title":"之江生物：累计回购公司股份2065434股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616239303","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616239303?lang=zh_cn&edition=full","pubTime":"2026-03-03 20:39","pubTimestamp":1772541540,"startTime":"0","endTime":"0","summary":"证券日报网讯 3月3日，之江生物发布公告称，截至2026年2月28日，公司通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份2，065，434股，占公司当前总股本192，157，999股的比例为1.07%，回购成交的最高价为23.49元/股，最低价为19.58元/股，支付的资金总额为人民币44，488，982.21元（不含印花税、交易佣金等交易费用）。本次回购股份符合相关法律法规的规定及公司的回购股份方案。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-03/doc-inhptkrh7466657.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-03/doc-inhptkrh7466657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2616333278","title":"之江生物去年营收1.25亿元，已连续三年营收下滑、净利亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2616333278","media":"新京报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616333278?lang=zh_cn&edition=full","pubTime":"2026-03-02 18:59","pubTimestamp":1772449140,"startTime":"0","endTime":"0","summary":"至此，之江生物已经连续三年营收下滑，净利亏损。2020年之前，之江生物的营业收入保持稳定增长，但尚不足3亿元。之江生物的业绩也随之大幅提升，2020年，其营业收入分别为20.52亿元，同比增长692.72%；同期，归母净利润分别为9.32亿元，同比增长1708.96%。2021年及2022年，之江生物的营收分别为20.19亿元、23.26亿元，归母净利润分别为7.59亿元、7.63亿元。新冠疫情红利消退后，之江生物业绩出现大幅下滑。","market":"sh","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/3/wangl882026321849162928526.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/3/wangl882026321849162928526.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1772449155168645.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1772449155168645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["688317"],"gpt_icon":0},{"id":"2616784503","title":"每周股票复盘：之江生物（688317）2025年净亏3430万","url":"https://stock-news.laohu8.com/highlight/detail?id=2616784503","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616784503?lang=zh_cn&edition=full","pubTime":"2026-03-01 03:14","pubTimestamp":1772306051,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，之江生物报收于21.07元，较上周的20.93元上涨0.67%。本周，之江生物2月25日盘中最高价报21.26元。本周关注点业绩披露要点：之江生物2025年净亏3430.38万元，同比减亏9315.83万元。公司公告汇总：之江生物预计2026年日常关联交易总额800万元。公司公告汇总：之江生物拟使用不超过8.6亿元闲置募集资金进行现金管理。业绩披露要点之江生物近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润亏损0.343亿元，同比增长73.09%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100001246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2614833108","title":"之江生物发布2025年度业绩快报，亏损0.343亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614833108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614833108?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:06","pubTimestamp":1772183168,"startTime":"0","endTime":"0","summary":"证券之星消息，之江生物近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润亏损0.343亿元，同比增长73.09%。报告期内，公司主要因集采政策陆续执行导致销售价格下降、自产试剂产品增值税税率调整为 13%和产品销量结构的变化等原因导致收入下降；财务收益的下降和汇兑损益减少等原因导致经营业绩亏损。公司成本费用管控措施落地见效，资产减值损失同比减少，2025年同比去年经营情况实现减亏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700027555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2614874198","title":"增持加码三优生物，之江生物深化“诊断+治疗”布局，业绩亏损泥潭待解","url":"https://stock-news.laohu8.com/highlight/detail?id=2614874198","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614874198?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:09","pubTimestamp":1772179793,"startTime":"0","endTime":"0","summary":"此番增持是之江生物落实“诊断+治疗”全产业链布局的重要举措。增持三优生物，巩固全产业链布局之江生物近日通过公司公众号发布信息，宣布完成对三优生物的新一轮战略增持。对于此次对三优生物的战略增持，之江生物表示，基于技术互补性与产业协同逻辑，进一步整合优势资源，巩固并深化在精准医疗下“诊断+治疗”的全产业链布局。2024年，之江生物营收规模缩减至1.79亿元，归属净利润亏损1.28亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026022700025195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2614503681","title":"之江生物（688317）披露2026年度日常关联交易预计公告，2月25日股价上涨0.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614503681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614503681?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:54","pubTimestamp":1772031254,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘，之江生物报收于21.14元，较前一交易日上涨0.43%，最新总市值为40.62亿元。近日，之江生物发布《关于2026年度日常关联交易预计的公告》。公告显示，公司于2026年2月24日召开第五届董事会第十八次会议，审议通过《关于2026年度日常关联交易预计的议案》，关联董事邵俊斌及倪卫琴对部分交易回避表决。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500038429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2609264705","title":"每周股票复盘：之江生物（688317）回购股份达总股本1.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609264705","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609264705?lang=zh_cn&edition=full","pubTime":"2026-02-08 03:16","pubTimestamp":1770491771,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，之江生物报收于21.55元，较上周的22.75元下跌5.27%。本周，之江生物2月2日盘中最高价报22.6元。截至2026年1月30日，公司累计回购股份1,940,434股，占公司总股本的1.01%，已支付金额41,869,022.21元，回购价格区间为19.58元/股至23.49元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800001188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2608930867","title":"之江生物（688317）披露2025年第三次以集中竞价交易方式回购公司股份比例达到总股本1%暨回购进展公告，2月2日股价下跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608930867","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608930867?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:14","pubTimestamp":1770041672,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，之江生物报收于21.6元，较前一交易日下跌5.05%，最新总市值为41.51亿元。近日，之江生物发布《关于2025年第三次以集中竞价交易方式回购公司股份比例达到总股本1%暨回购进展公告》。截至2026年1月30日，公司累计回购股份1,940,434股，占公司总股本的1.01%，已支付金额41,869,022.21元，回购价格区间为19.58元/股至23.49元/股。本次回购符合相关法规及公司方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200039145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2608591070","title":"每周股票复盘：之江生物（688317）因股价涨幅达15%登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2608591070","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608591070?lang=zh_cn&edition=full","pubTime":"2026-02-01 04:02","pubTimestamp":1769889740,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，之江生物报收于22.75元，较上周的21.29元上涨6.86%。本周，之江生物1月27日盘中最高价报28.58元。1月30日盘中最低价报22.43元。本周共计1次涨停收盘，无跌停收盘情况。之江生物当前最新总市值43.72亿元，在医疗器械板块市值排名87/127，在两市A股市值排名3858/5184。本周关注点来自交易信息汇总：之江生物因日收盘价格涨幅达到15%登上龙虎榜。此次是近5个交易日内第1次上榜。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2606021915","title":"1月26日之江生物（688317）龙虎榜数据：机构净买入1794.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606021915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606021915?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:28","pubTimestamp":1769423302,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年1月26日公布的交易公开信息显示，之江生物因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年1月26日收盘，之江生物报收于25.55元，上涨20.01%，涨停，换手率7.02%，成交量13.5万手，成交额3.36亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入1794.7万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600025359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2606267844","title":"异动快报：之江生物（688317）1月26日9点44分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2606267844","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606267844?lang=zh_cn&edition=full","pubTime":"2026-01-26 09:46","pubTimestamp":1769391981,"startTime":"0","endTime":"0","summary":"证券之星1月26日盘中消息，9点44分之江生物触及涨停板。其所属行业医疗器械目前上涨。领涨股为之江生物。该股为猴痘概念，肝炎概念，体外诊断概念热股，当日猴痘概念概念上涨1.06%，肝炎概念概念上涨0.55%，体外诊断概念上涨0.12%。1月23日的资金流向数据方面，主力资金净流入31.9万元，占总成交额1.01%，游资资金净流出237.26万元，占总成交额7.51%，散户资金净流入205.35万元，占总成交额6.5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600004397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2606237527","title":"每周股票复盘：之江生物（688317）2025年净利预亏3200万至4700万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606237527","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606237527?lang=zh_cn&edition=full","pubTime":"2026-01-25 03:34","pubTimestamp":1769283252,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，之江生物报收于21.29元，较上周的20.7元上涨2.85%。本周，之江生物1月23日盘中最高价报21.35元。之江生物当前最新总市值40.91亿元，在医疗器械板块市值排名94/127，在两市A股市值排名4097/5182。公司公告汇总：之江生物全自动核酸提取仪获马来西亚认证，有效期至2030年12月3日。业绩披露要点之江生物发布业绩预告，预计2025年全年归属净利润亏损3200万元至4700万元。预计2025年扣非后净利润亏损3900万元至5800万元，同比减亏54.78%至69.60%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500001285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2605490338","title":"之江生物（688317）披露2025年年度业绩预告，1月22日股价下跌0.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605490338","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605490338?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:47","pubTimestamp":1769093231,"startTime":"0","endTime":"0","summary":"截至2026年1月22日收盘，之江生物报收于20.86元，较前一交易日下跌0.05%，最新总市值为40.08亿元。该股当日开盘20.86元，最高20.96元，最低20.76元，成交额达1733.51万元，换手率为0.43%。公司近日发布公告，披露2025年年度业绩预告。公告显示，上海之江生物科技股份有限公司预计2025年年度归属于母公司所有者的净利润为-3,200.00万元到-4,700.00万元，同比减亏63.13%到74.89%；扣除非经常性损益后的净利润为-3,900.00万元到-5,800.00万元，同比减亏54.78%到69.60%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200041266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2605468021","title":"之江生物(688317.SH)发预亏，预计2025年度归母净亏损3200万元-4700万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605468021","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605468021?lang=zh_cn&edition=full","pubTime":"2026-01-22 15:36","pubTimestamp":1769067414,"startTime":"0","endTime":"0","summary":"智通财经APP讯，之江生物(688317.SH)发布2025年年度业绩预告，预计实现归属于母公司所有者的净利润-3,200万元到-4,700万元。与上年同期相比，净利润将减少亏损8,046.21万元到9,546.21万元，同比减亏幅度63.13%到74.89%。报告期公司业绩亏损的主要原因：公司主要产品销量下降、集采政策陆续执行导致价格下降和自产试剂产品增值税税率调整为13%导致收入下降;财务收益的下降和汇兑损益减少等原因导致业绩亏损。同时公司在积极应对市场竞争情况，加强产品研发，优化降本增效举措，挖掘潜力，不断提高产品的市场竞争力，提升公司经营能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"之江生物(688317.SH)发预亏，预计2025年度归母净亏损3200万元-4700万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2604311102","title":"之江生物（688317）披露公司产品获得相关认证，01月20日股价下跌0.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604311102","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604311102?lang=zh_cn&edition=full","pubTime":"2026-01-20 22:42","pubTimestamp":1768920134,"startTime":"0","endTime":"0","summary":"截至2026年1月20日收盘，之江生物报收于20.47元，较前一交易日下跌0.24%，最新总市值为39.33亿元。该股当日开盘20.53元，最高20.82元，最低20.31元，成交额达3072.27万元，换手率为0.78%。近日，之江生物发布关于自愿披露公司产品获得相关认证的公告。公告显示，上海之江生物科技股份有限公司全资子公司上海之江生物医药科技有限公司的全自动核酸提取仪获得马来西亚医疗器械管理局认证，认证编号IVDA3676725-218479，有效期至2030年12月3日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000039989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2604751167","title":"之江生物最新公告：公司产品获得马来西亚医疗器械认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2604751167","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604751167?lang=zh_cn&edition=full","pubTime":"2026-01-20 15:42","pubTimestamp":1768894936,"startTime":"0","endTime":"0","summary":"之江生物(688317.SH)公告称，公司全资子公司上海之江生物医药科技有限公司的全自动核酸提取仪（EX3600）近期获得马来西亚医疗器械管理局认证，可在马来西亚进行销售。该认证有助于提升公司国际竞争力，并推动海外销售产品品类及国际业务拓展。然而，产品面临市场竞争风险，且其销售额及利润贡献存在较大不确定性，对公司整体收入的影响也存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000018730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","159883","688317","BK1583","09996","BK1222","09997","BK1100"],"gpt_icon":0},{"id":"2602953675","title":"每周股票复盘：之江生物（688317）回购股份181.29万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602953675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602953675?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:21","pubTimestamp":1768076467,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，之江生物报收于21.19元，较上周的20.17元上涨5.06%。本周，之江生物1月8日盘中最高价报21.24元。本周关注点公司公告汇总：之江生物累计回购股份181.29万股，占公司总股本的0.94%。截至2025年12月31日，累计回购股份181.29万股，占公司总股本的0.94%，已支付资金总额3,913.02万元，实际回购价格区间为19.58元/股至22.86元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774373589253,"stockEarnings":[{"period":"1week","weight":-0.0357},{"period":"1month","weight":-0.0965},{"period":"3month","weight":-0.0698},{"period":"6month","weight":-0.1757},{"period":"1year","weight":0.1091},{"period":"ytd","weight":-0.0625}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.0492},{"period":"3month","weight":-0.0151},{"period":"6month","weight":0.0073},{"period":"1year","weight":0.1517},{"period":"ytd","weight":-0.0221}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海之江生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14435人(较上一季度减少7.74%)","perCapita":"13311股","listingDate":"2021-01-18","address":"上海市浦东新区张江高科技产业东区瑞庆路528号20幢乙号1层、21幢甲号1层","registeredCapital":"19215万元","survey":" 上海之江生物科技股份有限公司的主营业务是分子诊断试剂和仪器设备的研发、生产和销售。公司的主要产品是分子诊断试剂和仪器设备。公司共有500多项产品，已形成20大系列，是国内感染性疾病分子诊断产品最为齐全的企业之一，覆盖了绝大多数国家法定传染病。","listedPrice":43.22},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"之江生物(688317)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供之江生物(688317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"之江生物,688317,之江生物股票,之江生物股票老虎,之江生物股票老虎国际,之江生物行情,之江生物股票行情,之江生物股价,之江生物股市,之江生物股票价格,之江生物股票交易,之江生物股票购买,之江生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"之江生物(688317)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供之江生物(688317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}